What does Infigratinib treat?

Infigratinib/Infigratinib (Infigratinib) is an oral small molecule drug that belongs to a class of drugs called "serine kinase inhibitors". Its main function is to interfere with the growth and spread of cancer cells by inhibiting the activity of a protein called "serine kinase". Infigratinib/Infigratinib is often used to treat certain types of cancer, particularly those associated with abnormalities in the FGFR (fibroblast growth factor receptor) gene.

FGFRis a class of protein receptors involved in cell growth and differentiation. When combined with FGF (fibroblast growth factor), they can promote cell growth and division. However, when the FGFR gene is abnormal or mutated, it can lead to abnormal cell proliferation and the development of cancer. Infigratinib/Infigratinib inhibits the activity of FGFR, which can slow down or stop the growth of cancer cells and thus be used to treat related cancers.

Some common cancer types in which infitinib/infigratinib is used include cholangiocarcinoma (cholangiocarcinoma), urothelial cancer (urothelial carcinoma), glioblastoma (glioblastoma), lung cancer (lung cancer), etc. However, the specific indications and treatment options for Infigratinib/Infigratinib will vary based on the patient's condition and doctor's recommendations, so if you or someone you know has a related cancer condition, it is recommended to consult a medical professional for detailed diagnosis and treatment information. At the same time, the side effects and potential risks of medication should also be discussed with your doctor to ensure the best treatment plan.

Infigratinib/Infigratinib is not currently on the market in China, and it is unlikely to be included in medical insurance. Patients cannot purchase it domestically and can only purchase it through overseas channels. Foreign infigratinib/Infigratinib only has the original drug, the only American original drug, and the price is as high as about 200,000.